Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of YST-162 in Healthy Adults
NCT05310487Phase 1Completed
- Sponsor
- Yangshengtang
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing 162 (YST-162) with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Sep 2022; status: completed.
02
Drugs
YST-162
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05310487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310487.